The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Δημοσίευση

Under Development JAK Inhibitors for Dermatologic Diseases.

TitleUnder Development JAK Inhibitors for Dermatologic Diseases.
Publication TypeJournal Article
Year of Publication2020
AuthorsSideris, N., Vakirlis E., Tsentemeidou A., Kourouklidou A., Ioannides D., & Sotiriou E.
JournalMediterr J Rheumatol
Volume31
IssueSuppl 1
Pagination137-144
Date Published2020 Jun
ISSN2529-198X
Abstract

Molecular targeting therapies represent a new exciting era in dermatology. A promising novel drug class, subject of intense research, is Janus kinase (JAK) inhibitors. Multiple cytokine receptors signal through the Janus kinase and signal transducer and activator of transcription (STAT) pathway. The pathway plays a central role in innate and adaptive immunity, and haematopoiesis. The understanding of the contribution of JAKs to the immunologic processes of inflammatory diseases led to the development of JAK inhibitors, initially for rheumatologic and hematologic diseases. Soon, their efficacy in some dermatologic conditions was also demonstrated, and today their role as therapeutic agents is thoroughly researched, mainly in atopic dermatitis, psoriasis, vitiligo, and alopecia areata. JAK inhibitors can be administered orally or used topically. As they are relatively new treatment modalities in dermatology, many questions concerning their efficacy and safety remain unanswered. Data from ongoing trials are eagerly awaited. Here, we summarize under development JAK inhibitors for dermatologic diseases.

DOI10.31138/mjr.31.1.137
Alternate JournalMediterr J Rheumatol
PubMed ID32676572
PubMed Central IDPMC7361191

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.